Cranford, NJ
Intellectual property Lawyer at Cranford, NJ
Practice Areas: Intellectual Property, Life Sciences & Biotechnology ... +4 more
OUTCOME: pending
Lead counsel in IPR directed to U.S. Patent No. 7,919,499 directed to an extended release formulation of naltrexone marketed by Alkermes as VIVITROL®. The case is Amneal Pharmaceuticals LLC v. Alkerme ... s Pharma Ireland Ltd., Case No. IPR2018-00943 (Apr. 20, 2018).
OUTCOME: pending
Lead counsel in two IPRs directed to U.S. Patent Nos. 9,492,392 and 9,492,393. The '492 and '493 Patents are directed to sustained release formulations of oxycodone HCl, marketed by Purdue Pharma as Ox ... yContin®, and are two of 20+ patents that Purdue has asserted against Kashiv. The cases are Kashiv Pharma LLC v. Purdue Pharma, L.P. et al., Case Nos. IPR2018-00625 and -00717 (Feb. 27 and 28, 2018).
OUTCOME: Final Written Decision of invalidity of all claims
In a pair of Final Written Decisions issued in favor of Amneal and Kashiv, the Patent Trial and Appeal Board ("PTAB") held all challenged claims of U.S. Patent No. 9,034,376 invalid. The '376 Patent is ... directed to a sustained release formulation of oxycodone HCl, marketed by Purdue Pharma as OxyContin®, and is one of twenty patents that Purdue has asserted against Kashiv's ANDA directed to its own abuse-deterrent formulation of oxycodone. The cases are Amneal Pharmaceuticals, LLC v. Purdue Pharma, L.P. et al., Case Nos. IPR2016-01413, (Jan. 17, 2018) and IPR2016-01412 (Feb. 8, 2018).
OUTCOME: pending
Lead counsel for Cipla in multi-defendant first-to-file ANDA case regarding vortioxetine (TRINTELLIX®).
OUTCOME: Final Written Decision of invalidity of all claims
In a pair of Final Written Decisions issued in favor of Amneal and Kashiv, the Patent Trial and Appeal Board ("PTAB") held all challenged claims of U.S. Patent No. 9,060,976 invalid. The '976 Patent is ... directed to a sustained release formulation of oxycodone HCl, marketed by Purdue Pharma as OxyContin®, and is one of twenty patents that Purdue has asserted against Amneal and Kashiv. The cases are Amneal Pharmaceuticals, LLC v. Purdue Pharma, L.P. et al., Case Nos. IPR2016-01027 and -01028 (Nov. 8, 2017).
OUTCOME: pending
Counsel for Lotus and Alvogen in Hatch-Waxman litigation arising out of Lotus's ANDA directed to lenalidomide marketed by Celgene as REVLIMID®.
OUTCOME: pending
Lead counsel for InvaGen in multi-defendant first-to-file ANDA case regarding canagliflozin (INVOKANA®) and canagliflozin + metformin (INVOKAMET®).
OUTCOME: pending
Counsel for Torrent in Hatch-Waxman litigation arising out of Torrent's ANDAs directed to NESINA®, KAZANO®, AND OSENI®.
OUTCOME: pending
Lead counsel for Hengrui in Hatch-Waxman litigation arising out of Hengrui's ANDA for dexmedetomidine HCl 4 MCG/Ml ready-to-use products marketed by Hospira as PRECEDEX®.
OUTCOME: Final Written Decision of invalidity of all claims, affirmed on appeal
Tedd was part of the team of attorneys that prevailed in invalidating all challenged claims of two Orange Book-listed patents directed to Effient® (prasugrel). Lerner David was one of five firms repre ... senting a total of 20 named generic pharmaceutical Petitioners in two related Inter Partes Reviews. These decisions paved the way for the prevailing generics to launch their products as early as October 14, 2017. The cases are IPR2015-00864 and -00865 (Sept. 12, 2016), both of which were affirmed on appeal to the Federal Circuit.
Ad
Transform legal challenges into solutions.
Connect now to review your situation.
